Skip to main content

Table 2 Best Overall Response

From: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Group

Cohort 1 (N = 30)

Cohort 2 (N = 15)

Assessment 1 (N = 39)

Assessment 2 (N = 15)

Complete Response

3 (10%)

1 (7%)

4 (10%)

4 (27%)

95% CI (%)

(2, 27)

(0.2, 32)

(3, 24)

(8, 55)

Response (CR/PR)

8 (27%)

4 (27%)

11 (28%)

9 (60%)

95% CI (%)

(12, 46)

(8, 55)

(15, 45)

(33, 84)

Disease Control (CR/PR/SD)

23 (77%)

11 (73%)

30 (77%)

15 (100%)

95% CI (%)

(58, 90)

(45, 92)

(61, 89)

(78, 100)